Latest news and press releases about Lisata Therapeutics, Inc. (LSTA): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Lisata Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on pioneering and bringing to market cellular therapies. These treatments are designed to either reverse disease progression or facilitate the repair of damaged bodily tissues.
Price
| Price | $1.74 |
| Market Cap | $16M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 1.15 |
| EV / EBITDA | -0.01 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -111.65% |
| Return on Invested Capital | -117.30% |
| Return on Assets | -93.47% |
| Gross Margin | 14.12% |
| Operating Margin | -10711.18% |
| Net Margin | -9756.47% |
Related companies: CASI · CLGN · CLSD · ENLV · KLTO · MTVA · NCNA
Explore sector: Healthcare · Biotechnology
More sections of LSTA: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks